US Food and Drug Administration Approval of Drugs for the Treatment of Prostate Cancer: A New Era Has Begun

被引：29
作者：
D'Amico, Anthony V. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/JCO.2013.53.9528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：362 / 364
页数：3
相关论文
共 4 条
[1]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[2]   Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study [J].
Kantoff, PW ;
Halabi, S ;
Conaway, M ;
Picus, J ;
Kirshner, J ;
Hars, V ;
Trump, D ;
Winer, EP ;
Vogelzang, NJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2506-2513
[3]  
Leibowitz-Amit R, CURR OPIN SUPPORT PA
[4]   ESTRAMUSTINE PHOSPHATE SODIUM - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN PROSTATE-CANCER [J].
PERRY, CM ;
MCTAVISH, D .
DRUGS & AGING, 1995, 7 (01) :49-74
1